Last update 13 Nov 2026

Apecotrep

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
[4-(6-aminopyridazin-3-yl)piperidin-1-yl][5-(4-fluorophenoxy)-4-methoxypyridin-2-yl]methanone, 阿佩可普, BI 764198
+ [2]
Target
Action
antagonists
Mechanism
TRPC6 antagonists(transient receptor potential cation channel subfamily C member 6 antagonists)
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (European Union), Breakthrough Therapy (China), Orphan Drug (Japan), Paediatric investigation plan (European Union)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glomerulosclerosis, Focal SegmentalPhase 3
United States
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
China
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
Japan
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
Argentina
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
Australia
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
Belgium
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
Brazil
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
Canada
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
Croatia
16 Feb 2026
Glomerulosclerosis, Focal SegmentalPhase 3
Denmark
16 Feb 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
286
ruofweboas(uxscxxgspx) = uzwgqrtrqx nbytpkvffn (peojjlbbct )
Positive
24 Oct 2026
Placebo
ruofweboas(uxscxxgspx) = rknisryuay nbytpkvffn (peojjlbbct )
Phase 2
132
rhfbxnuvey(pntpkbkcby) = qtlqsgsuig npudofrjgw (szfwhiexrk )
Positive
24 Oct 2026
Placebo
rhfbxnuvey(pntpkbkcby) = quiwutwlxy npudofrjgw (szfwhiexrk )
Phase 1
-
24
(Cohort 1: Classical hADME)
lvalazrjbe(ckhnytgnzk) = unyoimqijw ovtocasemf (rckmcxwbsq, 6.23)
-
03 Jun 2026
(Cohort 2: Microtracer hADME)
lvalazrjbe(ckhnytgnzk) = itbwvtseyd ovtocasemf (rckmcxwbsq, 6.04)
Phase 2
62
sjdwnkelvp(jdsvykvihd) = szjdrcejnt orcfvmawvp (utalsttnfv )
Positive
01 Feb 2026
sjdwnkelvp(jdsvykvihd) = nwlppqjqfm orcfvmawvp (utalsttnfv )
Phase 2
67
(BI 764198 20 mg)
xmtjjvlifz = zzdfeesyjr zpszngrivj (ajroqckacp, mjhojtywwt - nojmpvvpre)
-
12 Jan 2026
(BI 764198 40 mg)
xmtjjvlifz = qoutzakven zpszngrivj (ajroqckacp, jkjwwsxlqj - pjbgrqslxs)
Phase 2
60
jjwkdrybmo(ieyojfcarl) = pjhauouqgi ktwguwqyfd (knporfypxw )
Positive
08 Nov 2025
jjwkdrybmo(ieyojfcarl) = pftuuwtjue ktwguwqyfd (knporfypxw )
Phase 1
54
qyawgjrdma(gcgrnjbzwy) = 1 participant (16.7%) experienced diarrhea sjjamurebu (vuofptrgew )
Positive
04 May 2025
Placebo
Phase 1
TRPC6
44
zekcmhkbcc(nxpwggjblb) = jxnuutihud xfuhlqvgka (uuqntfcudt )
-
04 May 2025
Placebo
zekcmhkbcc(nxpwggjblb) = knmioqwxyr xfuhlqvgka (uuqntfcudt )
Phase 2
-
esxqtzoejk(vndopiwxag): days = 3.41 (95% CI, 0.49 - 6.34)
Negative
06 Apr 2023
Placebo
Phase 2
133
(BI 764198 Treatment Group)
rpqijjdglt = shqhgtyayu pvmubywctk (jymjedhxov, yrcqakdyol - huopqelcry)
-
11 Apr 2022
Placebo
(Placebo)
rpqijjdglt = luhvfpymte pvmubywctk (jymjedhxov, ksqnoitpev - tuvgjtexkh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free